as of 09-11-2026 4:00pm EST
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.
| Founded: | N/A | Country: | Switzerland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 263.0M | IPO Year: | 2025 |
| Target Price: | N/A | AVG Volume (30 days): | 380.8K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $1.27 - $4.50 | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
Director
Avg Cost/Share
$1.50
Shares
50,000
Total Value
$75,000.00
Owned After
5,773,618
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$1.53
Shares
5,000
Total Value
$7,650.00
Owned After
5,000
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Baumann Oliver Rolf | VRXA | Director | Aug 27, 2026 | Buy | $1.50 | 50,000 | $75,000.00 | 5,773,618 | |
| Antz Christoph Rudiger | VRXA | Chief Executive Officer | Aug 27, 2026 | Buy | $1.53 | 5,000 | $7,650.00 | 5,000 |
See how VRXA stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "VRXA Veraxa Biotech AG Ordinary Shares - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.